Overview

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

Status:
Terminated
Trial end date:
2020-05-21
Target enrollment:
Participant gender:
Summary
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-936 following single ascending oral doses in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Cerevel Therapeutics, LLC